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New oral anticoagulants (NOACs) have emerged as an alternative
for vitamin K antagonists (VKAs) for thrombo-embolic prevention
in patients with non-valvular atrial ﬁbrillation (AF). Although very
promising in many regards (predictable effect without need for
monitoring, fewer food and drug interactions, shorter plasma
half-life, and an improved efﬁcacy/safety ratio), the proper use of
NOACswill require new approaches inmany daily aspects. While
the 2010 ESC Guidelines (and the 2012 Update) mainly discuss the
indications for anticoagulation in general (based on the
CHA2DS2-VASc score) and of NOAC in particular, they guide less
on how to deal with NOAC in speciﬁc clinical situations. The
European Heart Rhythm Association (EHRA) set out to coordinate
a uniﬁed way of informing physicians on the practical use of the
different NOACs, in a text that supplements the AF Guidelines as
a guidance tool for safe, effective use of NOAC when prescribed.Table 1 – New anticoagulant drugs, approved or under evaluatio
with non-valvular atrial ﬁbrillation.Please note that all drugs discussed in this document
may not already be EMA approved for the non-valvular AF
indication, and/or may not be available in the different
constituent EU countries at the time of publication of this
document. Since new information is becoming available at a
rapid pace, an EHRA web site with the latest updated informa-
tion accompanies this text (http://www.NOACforAF.eu, which
links to http://www.escardio.org/ COMMUNITIES/EHRA, under
‘Publications’). Any item that has been changed from the
original printed version will be highlighted in the future.2. Practical start-up and follow-up scheme for
patients on new oral anticoagulants
Before prescribing a NOAC (Table 1) to a patient with AF,
a risk–beneﬁt analysis should be made concerning anti-n for prevention of systemic embolism or stroke in patients
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6e44coagulation in general and the choice of the speciﬁc anti-
coagulant on the basis of approved indications and on the
preference of the patient after discussion of the differentFig. 1 – European Heart Rhythm Association proposal for a unive
crucial, both for the patient (instructions on correct intake; contac
(other care-takers are involved; renal function; follow-up schedu
universal card that could serve all patients under NOAC therapyoptions. Concerning the choice of a given NOAC, it is also
important to consider the clinical proﬁle of the patient and
co-medications, some of which may be contraindicated orrsal NOAC anticoagulation card. A patient information card is
t information in case of questions) as for health care workers
le; concomitant medication…). We present a generic and
.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6 e45pose unfavourable drug–drug interactions. As for users of
VKAs, it is equally important that those treated with NOACs
carry details about their anticoagulant therapy to alert any
(para-)medical participant in their care. We propose a uni-
form card to be completed and carried by each patient (Fig. 1).
It can be downloaded in digital form at http://www.NOAC
forAF.eu. The goal of the card is not only to list demographic
and medication information, and to educate the patient, but
mainly to structure a coordinated follow-up of the patient by
different caregivers. The structure of initiation and follow-up
is shown in Fig. 2. A checklist for actions during the follow-up
contacts is presented in Table 2. Therapy with this new class
of drugs requires vigilance, also because this is a fragile
patient population and NOACs are drugs with potentially
severe complications. Patients should return on a regular
basis for on-going review of their treatment, preferably every
3 months. This review may be undertaken by general practi-
tioners provided that they have good guidance on what to do
and when. The card also lists the appropriate timing of
laboratory testing, taking the patient proﬁle into considera
tion. Renal function should be assessed more frequently in
patients receiving dabigatran, or in potentially compromised
patients such as the elderly, otherwise frail patients, or in
those where an intercurring condition may affect renalInitiator of anticoagulant treatment:
First FU: 1 month
1 m?
3 m
6 m
Else: Fills out anticoagulation card and sets date/place
for next follow-up.
In case of problems: contacts initiator of treatment.
Follow-up: GP; anticoagulant clinic; initiator of therapy; ...
- Checks:
1. Compliance (patient should bring remaining oills);
2. Thrombo-embolic events;
3. Bleeding events;
4. Other side effects;
5. Co-medications and over-the-counter drugs;
6. Need for blood sampling?
- Sets indication for anticoagulation;
- Makes choice of anticoagulant;
- Decides on need of proton pump inhibitor;
- Baseline hemoglobin, renal and liver function;
- Provides education;
- Hands out anticoagulation card;
- Organises follow-up (when, by whom, what?);
- Remains responsible coordinator for follow-up.
Fig. 2 – Structured follow-up of patients on NOACs. It is
mandatory to ensure safe and effective drug intake. The
anticoagulation card, as proposed in Fig. 1, is intended to
document each planned visit, each relevant observation or
examination, and any medication change, so that every
person following up the patient is well-informed. Moreover,
written communication between the different (para)medical
players is required to inform them about the follow-up plan
and execution.function, since all NOACs require dose reductions depending
on renal function.3. How to measure the anticoagulant effect of
new oral anticoagulants?
New oral anticoagulants do not require routine monitoring of
coagulation: neither the dose nor the dosing intervals should
be altered in response to changes in laboratory coagulation
parameters. However, the quantitative assessment of the
drug exposure and the anticoagulant effect may be needed
in emergency situations. When interpreting a coagulation
assay in a patient treated with a NOAC, in contrast to VKA
coagulation monitoring, it is paramount to know exactly
when the NOAC was administered relative to the time of
blood sampling. The time delay between intake and blood
sampling should, therefore, be carefully recorded when bio-
logical monitoring is performed. A complete overview of the
effect on common coagulation assays by direct thrombin
inhibitors (DTI) and FXa inhibitors can be found in Table 3.
The activated partial thromboplastin time (aPTT) may pro-
vide a qualitative assessment of the presence of dabigatran.
If the aPTT level at trough (i.e. 12–24 h after ingestion)
still exceeds two times the upper limit of normal, this may
be associated with a higher risk of bleeding, and may
warrant caution especially in patients with bleeding risk
factors. The prothrombin time (PT) may provide a qualita-
tive assessment of the presence of factor Xa inhibitors. Like
the aPTT for dabigatran, these respective tests are not
sensitive for the quantitative assessment of the NOAC
effect! Quantitative tests for DTI and FXa inhibitors do exist
(diluted thrombin-time and chromogenic assays, respec-
tively), but they may not (yet) be routinely available in most
hospitals. Moreover, there are no data on a cut-off of these
speciﬁc tests below which elective or urgent surgery is ‘safe’,
and therefore their use in this respect cannot be recom-
mended at this time. Point of care tests to assess the
international normalised ratio (INR) should not be used in
patients on NOACs.4. Drug–drug interactions and
pharmacokinetics of new oral anticoagulants
Despite high expectations of less food interactions with the
NOAC drugs, physicians will have to consider pharmacoki-
netic effects of accompanying drugs and of comorbidities
when prescribing NOACs, especially when a combination of
interfering factors is present. The absorption and metabolism
of different NOACs is summarised in Table 4. There is a good
rationale for reducing the dose of NOACs in patients with a
high bleeding risk and/or when a higher plasma level of the
drug can be anticipated. We have chosen an approach with
three levels of alert for drug–drug interactions or other
clinical factors that may affect NOAC plasma levels or effects
(Table 5): (1) ‘red’ interactions reclude the use of a given
NOAC in combination (i.e. ‘contraindication’ or ‘discourage-
ment’ for use), (2) ‘orange’ interactions refer to the recom-
mendation to adapt the NOAC dose, since they result in
Table 2 – Checklist during follow-up contacts of AF patients on anticoagulation.
Interval Comments
1. Compliance Each visit Instruct patient to bring remaining medication: note and calculate average adherence
Re-educate on importance of strict intake schedule
Inform about compliance aids (special boxes; smartphone applications;…)
2. Thrombo-embolism Each visit Systemic circulation (TIA, stroke, peripheral)
Pulmonary circulation
3. Bleeding Each visit ˈNuisanceˈ bleeding: preventive measures possible? (PPI; haemorrhoidectomy;…).
Motivate patient to diligently continue anticoagulation
Bleeding with impact on quality/of/life or with risk: prevention possible?
Need for revision of anticoagulation indication or dose?
4. Other side effects Each visit Carefully assess relation with NOAC: decide for continuation (and motivate),
temporary cessation (with bridging), or change of anticoagulant drug.
5. Co-medications Each visit Prescription drugs; over-the-counter drugs (see Section 4)
Careful interval history: also temporary use can be risk!
6. Blood sampling Yearly Haemoglobin, renal and liver function
6 monthly Renal function if CrCl 30–60 ml/min, or if on dabigatran and 475 years of fragile
3 monthly If CrCl 15–30 ml/min
On indication If intercurring condition that may impact renal or hepatic function
TIA, transient ischaemic attack; PPI, proton pump inhibitor; CrCl, creatinine clearance (preferably measured by the Cockroft method).
Table 3 – Interpretation of coagulation assays in patients treated with different NOACs.
Dabigatran Apixaban Edoxabana Rivaroxaban
Plasma peak
level
2 h after ingestion 1–4 h
after
ingestion
1–2 h after ingestion 2–4 h after ingestion
Plasma
trough level
12–24 h after ingestion 12–24 h
after
ingestion
12–24 h after ingestion 16–24 h after ingestion
PT Cannot be used Cannot be
used
Prolonged but no known relation
with bleeding risk
Prolonged: may indicate excess
bleeding risk but local calibration
required
INR Cannot be used Cannot be
used
Cannot be used Cannot be used
aPTT At trough: 42 ULN
suggests excess bleeding
risk
Cannot be
used
Prolonged but no known relation
with bleeding risk
Cannot be used
dTT At trough: 4200 ng/ml or
465 s: excess bleeding
risk
Cannot be
used
Cannot be used Cannot be used
Anti-FXa
chromogenic
assays
Not applicable No data
yet
Quantitative; no data on threshold
values for bleeding or thrombosis
Quantitative; no data on threshold
values for bleeding or thrombosis
ECT At trough: Z3 ULN:
excess bleeding risk
Not
affected
Not affected Not affected
Routine monitoring is not required. Assays need cautious interpretation for clinical use in special circumstances, as discussed in the text.
PT, prothrombin time; aPTT, activated partial thromboplastin time; dTT, diluted thrombin time; INR, international normalised ratio; ULN,
upper limit of normal.
a No EMA approval yet. Needs update after ﬁnalisation of SmPC.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6e46changes of the plasma levels or effect of NOACs that could
potentially have a clinical impact, and (3) ‘yellow’ interac-
tions with the recommendation to keep the original dose,
unless two or more concomitant ‘yellow’ interactions are
present. Two or more ‘yellow’ interactions need expert
evaluation, and may lead to the decision of not prescribingthe drug (‘red’) or of adapting its dose (‘orange’). Unfortu-
nately, for many potential interactions with drugs that are
often used in AF patients no detailed information is available
yet. These have been shaded in the Table. It is prudent to
abstain from using NOACs in such circumstances until more
information is available.
Table 4 – Absorption and metabolism of the different NOACs.
Dabigatran Apixaban Edoxabana Rivaroxaban
Bio-availability 3–7% 50% 62% 66% without
food
Almost 100%
with food
Prodrug Yes No No No
Clearance non-renal/renal of absorbed dose (if
normal renal function; see also Section 8)
20%/80% 73%/27% 50%/50% 65%/35%
Liver metabolism: CYP3A4 involved No Yes (elimination; minor
CYP3A4 contribution)
Minimal (o4% of
elimination)
Yes
(elimination)
Absorption with food No effect No effect 6–22% more þ39% more
Intake with food recommended? No No No ofﬁcial
recommendation
yet
Mandatory
Absorption with H2B/PPI 12–30% No effect No effect No effect
Asian ethnicity þ25% No effect No effect No effect
Gl tolerability Dyspepsia
5–10%
No problem No problem No problem
Elimination half-life 12–17 h 12 h 9–11 h 5–9 h
(young)
11–13 h
(elderly)
H2B, H2-blocker; PPI, proton pump inhibitor; Gl, gastro-intestinal.
a No EMA approval yet. Needs update after ﬁnalisation of SmPC.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6 e47Since food intake has an impact on the absorption and
bioavailability of rivaroxaban (area under the curve plasma
concentrations increase by 39%), rivaroxaban should be taken
together with food. There is no relevant food interaction for the
other NOAC and they may be taken with or without food. Also,
concomitant use of proton-pump inhibitors (PPI) and H2-
blockers does not constitute a contraindication for any NOAC.
Rate-controlling and anti-arrhythmic drugs interact with
P-gp, hence warranting caution for concomitant use of
NOACs. For dabigatran and edoxaban it is advised to reduce
the NOAC dose when used in combination with verapamil
(‘orange’). There is a strong effect of dronedarone on dabiga-
tran plasma levels, which constitutes a contraindication for
concomitant use. No data are available yet for FXa-inhibitors,
but a similar caution may be warranted.
Apart from the pharmacokinetic interactions, it is clear that
association of NOACs with other anticoagulants, platelet inhi-
bitors (aspirin, clopidogrel, ticlodipine, prasugrel, ticagrelor, and
others), and non-steroidal anti-inﬂammatory drugs (NSAID)
increases the bleeding risk. There is data indicating that the
bleeding risk in association with antiplatelet agents increases by
at least 60% (similar as in association with VKAs). Therefore,
such associations should be carefully balanced against the
potential beneﬁt in each clinical situation. Association of NOACs
with (dual) antiplatelet drugs is extensively discussed in ‘Patient
with atrial ﬁbrillation and coronary artery disease’ below.5. Switching between anticoagulant regimens
It is important to safeguard the continuation of anticoagu-
lant therapy while minimising the risk for bleeding whenswitching between different anticoagulant therapies. This
requires insights into the pharmacokinetics and pharma-
codynamics of different anticoagulation regimens, inter-
preted in the context of the individual patient. Practical
switching scenarios have been described in the full docu-
ment [1], for VKA or a parenteral anticoagulant to NOAC
and vice versa.NOACs can immediately be initiated once the INR is lower
than 2.0. If the INR is 2.0–2.5, NOACs can be started next day.
NOACs can be started once the intravenous UFH is
discontinued.
NOACs can be initiated when the next dose of LMWH
would have been foreseen.Especially for the circumstances where NOAC treatment
should be switched to VKA, caution is required: due to the
slow onset of action of VKAs, it may take 5–10 days before an
INR in therapeutic range is obtained, with large individual
variations. Therefore, the NOAC and the VKA should be
administered concomitantly until the INR is in a range that
is considered appropriate. Since NOACs may have an addi-
tional impact on the INR (especially the FXa inhibitors),
inﬂuencing the measurement while on combined treatment
during the overlap phase, it is important (1) that the INR be
measured just before the next intake of the NOAC during
concomitant administration, and (2) be re-tested 24 h after
the last dose of the NOAC (i.e. sole VKA therapy) to assure
adequate anticoagulation. It is also recommended to closely
monitor INR within the ﬁrst month until stable values have
been attained (i.e. three consecutive measurements should
have yielded values between 2.0 and 3.0).
Table 5 – Effect on NOAC plasma levels (‘area under the curve, AUC’) from drug-drug interactions and clinical factors, and
recommendations towards NOAC dosing.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6e486. Ensuring compliance with new oral
anticoagulant intake
New oral anticoagulants have a very predictable anticoagu-
lant effect. Monitoring of the anticoagulant effect is not
required to guide therapy, unless in unusual clinical situa-
tions (like intercurrent disease). However, the anticoagulanteffect of NOACs fades rapidly (12–24 h after the last intake).
Therefore, strict therapy compliance by the patient is crucial.
Even if appropriate new anticoagulation tests would be used
to gauge NOAC plasma levels, they cannot be considered as
tools to monitor compliance since their interpretation is
highly dependent on the timing of testing with respect to
the last intake of the drug, and they do not indicate anything
about compliance before the last intake. Physicians should
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6 e49develop ways to optimise compliance, which is known to be
r80% for most drugs in daily practice.6.1. Practical considerations:(1) A once daily (qd) dosing regimen was related to greater
adherence vs. bid regimen in cardiovascular patients, and
in AF patients (for diabetes and hypertension drugs). It is
likely that also for NOACs a qd dosing regime is best from
a compliance perspective, but it is unknown whether any
regimen is superior in guaranteeing the clinical throm-
boembolic preventive effects and the safety proﬁle as seen
in the clinical trials.(2) Patient education on the importance of strict adherence is
of utmost importance. Many simultaneous approaches
should be employed in this regard: leaﬂets and instructions
at initiation of therapy; a patient anticoagulation card; group
sessions; and reeducation at every prescription renewal.
There is room and potentially a need to develop new tools
to enhance compliance with NOACs.(3) Family members should be involved in this education, so
that they too understand the importance of adherence,
and help the patient in this regard.(4) Although INR monitoring is not required, there should be
a prespeciﬁed follow-up schedule between general practi-
tioner, cardiologist, or electrophysiologist, and the
responsibility of each concerning compliance should be
clearly communicated. There is emerging interest in
nurse-coordinated AF centres that may speciﬁcally focus
on compliance issues during patient follow-up.(5) Many technological aids are being explored to enhance
compliance: the format of the blisters; medication boxes,
smartphone applications, and/or SMS messages that alert
the patient about the next intake;… Again, their long-term
effects are unknown and one tool may not ﬁt all patients.
The prescribing physician, however, should consider indi-
vidualisation of these aids.(6) Some patients may prefer INR monitoring to no monitoring.
This needs to be discussed with the patient before starting/
converting to NOAC therapy. In some patients, there may be
a preference for VKA treatment from this perspective.(7) Some countries have a highly networked pharmacy data-
base, which can help track the number of NOAC prescrip-
tions that individual patients claim. In such countries,
pharmacists could be involved in compliance monitoring.(8) In NOAC patients in whom low compliance is suspected
despite proper education and additional tools, conversion
to VKAs could be considered.
7. How to deal with dosing errors?
7.1. Missed dose
No double dose should be taken to make up for missed
individual doses. For NOACs with a bid dosing regimen (i.e.
every 12 h), the patient should still take a forgotten dose up
till 6 h after the scheduled intake. If that is not possible
anymore, the dose should be skipped and the next scheduled
dose should be taken. For NOACs with a qd dosing regimen,the patient should still take a forgotten dose up till 12 h after
the scheduled intake. If that is not possible anymore, the
dose should be skipped and the next scheduled dose should
be taken.7.2. Double dose
For NOACs with a bid dosing regimen, one could opt to forgo
the next planned dose (i.e. after 12 h), and restart bid intake
from after 24 h. For NOACs with a qd dosing regimen, the
patient should continue the normal dosing regimen, i.e.
without skipping the next daily dose.7.3. Uncertainty about dose intake
Sometimes, the patient is not sure about whether a dose has
been taken or not. For NOACs with a bid dosing regimen, one
could advise to not take another pill, but to just continue the
planned dose regimen, i.e. starting with the next dose at the
12 h interval. For NOACs with a qd dosing regimen, one could
advise to take another pill and then continue the planned
dose regimen.7.4. Overdose
Depending on the amount of suspected overdose, hospitali-
sation for monitoring or urgent measures should be advised.
For further discussion, see Section 10.8. Patients with chronic kidney disease
Chronic kidney disease (CKD) constitutes a risk factor for both
thrombo-embolic events and bleeding in AF patients. Recent
ﬁndings suggest that a creatinine clearance of ,60 ml/min
may even be an independent predictor of stroke and systemic
embolism.
Many patients with mild-tomoderate CKD have been
enrolled in the NOAC trials. For FXa inhibitors, pharmacoki-
netic studies have demonstrated similar plasma area under
the curve concentrations for reduced doses in patients with
decreased renal function (CrCl 30–50 ml/min) as for the
higher dose in patients with normal renal function, and these
doses have been prospectively tested in phase 3 trials. In the
context of NOAC treatment, CrCl is best assessed by the
Cockroft method, as this was used in most NOAC trials.
Rivaroxaban is also approved for use in patients with CKD
stage IV, i.e. CrCl 15–30 ml/min, with the lower dose regimen,
although it should still be used ‘with caution’ in such
patients. However, there are no outcome data for NOACs in
patients with advanced chronic kidney disease, and the
current ESC Guidelines recommend against their use in such
patients (Table 6). Furthermore, there are very little data on
patients on dialysis or close to dialysis (glomerular ﬁltration
rate ,15 ml/min, CKD stage V), neither from trials nor from
clinical experience. In the absence of such experience, no
NOAC is approved for use in dialysis patients.
Table 6 – Estimated drug half-lives and effect on area under the curve NOAC plasma concentrations in different stages of
chronic kidney disease compared to healthy controls.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6e508.1. Practical suggestions(1) Chronic kidney disease should be considered as an addi-
tional risk factor for stroke in AF. But CKD also increases
bleeding risk, with a relative increase in risk for all oral
anticoagulants (VKA and NOACs).(2) New oral anticoagulants seem to be a reasonable choice
for anticoagulant therapy in AF patients with mild or
moderate CKD. A similar beneﬁt/risk ratio of NOACs vs.
VKAs was seen with a reduced dose rivaroxaban (15 mg
qd) in patients with renal impairment (CrCl ,50 ml/min).
Apixaban, demonstrated a lower overall rate of major
bleeding compared to VKA, and also that the increase in
the rate of bleeding by renal dysfunction was signiﬁcantly
less than with VKA. Of note, in the group of patients with
a CrCl ,50 ml/min, 24% received a lower dose of apixaban
(i.e. 2.5 mg bid) since dose reduction was prespeciﬁed
according to a combination of renal dysfunction (serum
creatinine Z1.5 mg/dl) plus age (Z80 years) or body
weight (r60 kg) (Table 7).(3) There are no comparative studies that the risks from CKD
differ among the NOACs. In light of the potential impact
of further renal function ﬂuctuations, dabigatran, which
is primarily cleared renally, may not be the NOAC of ﬁrst
choice in patients with known CKD, especially stage III or
higher. On the other hand, there was no signiﬁcant
interaction between the relative risk/beneﬁt of dabigatran
vs. VKAs depending on kidney function. Therefore, careful
balancing of the clinical beneﬁts and risks may justify its
choice in stable patients. Also the FXa inhibitors are
cleared 25–50% by the kidney (Table 4). Dose reductions
have been studied prospectively with apixaban (2.5 mg
bid) and rivaroxaban (15 mg qd), and should be considered
in patients with CrCl ,50 ml/min along the guidance of
Tables 4 and 6.(4) In the absence of clinical data or experience, NOAC
therapy should be avoided in AF patients on haemodia-
lysis. Vitamin K antagonists may be a more suitable
alternative for now.(5) In patients on NOACs, renal function needs to be mon-
itored carefully, at least yearly, to detect changes in renal
function and adapt the dose accordingly. If renal functionis impaired (r60 ml/min), 6 monthly checks are required.
Renal function monitoring is especially relevant for
dabigatran, which is predominantly cleared renally: in
elderly patients (.75 years) or otherwise frail patients on
dabigatran, renal function should be evaluated at least
once every 6 months (see also Table 2 and Fig. 2). Acute
illness often transiently affects renal function (infections,
acute heart failure…), and therefore should trigger re-
evaluation.(6) Renal function can deteriorate within a few months, and
the nature of the kidney disease as well as concomitant
conditions that could change the time course of CKD
should be considered when deciding on a monitoring
scheme.
(i) Monitor every year for CKD stage I–II (CrCl Z60 ml/
min).
(ii) Monitor every 6 months for CKD stage III (CrCl 30–
60 ml/min).
(iii) Monitor every 3 months for CKD stage IV (CrCl
r30 ml/min).9. What to do if there is a (suspected) overdose
without bleeding, or a clotting test is indicating a
risk of bleeding?
Doses of NOACs beyond those recommended expose the
patient to an increased risk of bleeding. This may occur when
the patient has taken too high a dose or when intercurring
events are suspected (like renal insufﬁciency, especially with
dabigatran; administration of drugs that may lead to drug–
drug interactions; or other factors: see Section 5) that may
have increased plasma concentration of the NOAC beyond
therapeutic levels. In terms of management, it is important
to distinguish between an overdose with and without bleed-
ing complications. In case of bleeding complications, see
Section 10. Rare cases of overdose have been reported with-
out bleeding complications or other adverse reactions in the
clinical trials. In the case of recent acute ingestion of an
overdose, the use of activated charcoal to reduce absorption
may be considered for any NOAC (with a standard dosing
scheme for adults of 30–50 g). In case of an overdose suspi-
cion, coagulation tests can help to determine its degree and
Table 7 – NOACs in renal dysfunction: Approved European labels and dosing in chronic kidney disease.
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coagulation tests).
There are currently no speciﬁc antidotes for the NOACs,
although development for those is ongoing. However, given
the relatively short plasma half life of the NOAC drugs, in the
absence of bleeding a ‘wait-and-see’ management can be
advocated in most cases.10. Management of bleeding complications
At this point in time the different NOACs share the fact that
speciﬁc antidotes and rapid (routine) quantitative measure-
ments of their anticoagulant are missing (see also Section 3),
and strategies for reversal of the anticoagulant effects are
limited.10.1. Non life-threatening bleeding
In addition to standard supportive measurements (such as
mechanical compression, surgical haemostasis, ﬂuid replace-
ment, and other haemodynamic support), in view of the
relatively short elimination half lives, time is the most
important antidote of the NOACs (see Table 8 and Fig. 3 for
a ﬂowchart). After cessation of treatment, restoration of
haemostasis is to be expected within 12–24 h after the last
taken dose, given plasma half-life of around 12 h for most
NOACs. This underscores the importance of inquiring
about the used dosing regimen, the exact time of last intake,
factors inﬂuencing plasma concentrations (like P-gp therapy,
chronic kidney disease, and others, see also Table 5), and
other factors inﬂuencing haemostasis (like concomitant use
of anti-platelet drugs). Blood volume repletion and restora-
tion of normal platelet count (in case of thrombocytopenia
Bleeding while using a NOAC
Mild bleeding
•  Delay or discontinue next dose
•  Mechanical compression
•  Surgical hemostasis
•  Fluid replacement (colloids if needed)
•  PCC (e.g. CoFact®) 25 U/kg; repeat 1×/2× if indicated
•  aPCC (Feiba®) 50IE/kg; max 200 IE/kg/day
•  (rFVIIa (NovoSeven®) 90 µg/kg no data about
    additional benefit)
•  RBC substitution if needed
•  Fresh frozen plasma (as plasma expander)
•  Platelet substitution (if platelet count <60×109/L)
•  Maintain adequate diuresis
•  Consider hemodialysis
•  ((charcoal haemoperfusion?: await more data))
Supportive measures:
For dabigatran:
Consider:
++
•  Reconsoder concomitant medication
Moderate severe bleeding Life-threatening bleeding
Fig. 3 – Management of bleeding in patients taking NOACs. Possible therapeutic measures in case of minor or severe bleeding
in patients on NOAC therapy.
Table 8 – Possible measures to take in case of bleeding.
Direct thrombin inhibitors (dabigatran) FXa inhibitors (apixaban, edoxaban, rivaroxaban)
Non life-
threatening
bleeding
Enquire last intakeþdosing regimen Enquire last intakeþdosing regimen
Estimate normalisation of haemostasis: Normalisation of haemostasis: 12–24 h
Normal renal function: 12–24 h
CrCl 50–80 ml/min: 24–36 h
CrCl 30–50 ml/min: 36–48 h
CrCl o30 ml/min Z48 h
Maintain diuresis
Local haemostatic measures Local haemostatic measures
Fluid replacement (colloids if needed) Fluid replacement (colloids if needed)
RBC substitution if necessary RBC substitution if necessary
Platelet substitution (in case of thrombocytopenia
r60 109/L or thrombopathy)
Platelet substitution (in case of thrombocytopenia
r60 109/L or thrombopathy)
Fresh frozen plasma as plasma expander (not as reversal
agent)
Fresh frozen plasma as plasma expander (not as reversal
agent)
Tranexamic acid can be considered as adjutants Tranexamic acid can be considered as adjutants
Desmopressin can be considered in special cases
(coagulopathy or thrombopathy)
Desmopressin can be considered in special cases
(coagulopathy or thrombopathy)
Consider dialysis (preliminary evidence: 65% after 4 h)
Charcoal haemoperfusion not recommended (no data)
Life-
threatening
bleeding
All of the above All of the above
Prothrombin complex concentrate (PCC) 25 U/kg (may be
repeated once or twice) (but no clinical evidence)
Prothrombin complex concentrate (PCC) 25 U/kg
(may be repeated once or twice) (but no clinical evidence)
Activated PCC 50 IE/kg; max 200 IE/kg/day: no strong data
about additional beneﬁt over PCC. Can be considered
before PCC if available
Activated factor VII (rFVIIa; 90 mg/kg) no data about
additional beneﬁtþexpensive (only animal evidence)
Activated PCC 50 IE/kg; max. 200 IE/kg/day): no strong data
about additional beneﬁt over PCC. Can be considered before
PCC if available
Activated factor VII (rFVIIa; 90 mg/kg) no data about
additional beneﬁtþexpensive (only animal evidence)
RBC, red blood cells; CrCl, creatinine clearance; PCC, prothrombin complex concentrate.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 2 – e 5 6e52r60109/L or thrombopathy) should be considered. The
time frame of drug elimination strongly depends on kidney
function in patients taking dabigatran (see also Tables 4
and 6). In case of bleeding in a patient using dabigatran,
adequate diuresis must be maintained. Although dabigatrancan be dialysed, it should be noted that there is only limited
clinical experience in using dialysis in this setting. Moreover,
the risks of bleeding at puncture sites for dialysis needs to be
balanced vs. the risk of waiting. In contrast to dabigatran,
dialysis has not been shown to be an option in patients
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plasma binding of most FXa inhibitors, dialysis is not
expected to signiﬁcantly reduce their plasma levels.10.2. Life-threatening bleeding
In vitro testing using blood samples from volunteers taking
rivaroxaban, dabigatran, or apixaban, showed that activated
prothrombin complex concentrates (aPCC, i.e. similar to PCC
but with activated Factor VIIa; also called FEIBA; brand name
Feibas) corrected more coagulation parameters than PCC alone.
Based on experimental data and given that the efﬁcacy
in patients who are actively bleeding has not been ﬁrmly
established (i.e. that they reduce blood loss and improve
outcome), the administration of PCC or aPCC can be consid-
ered in a patient with life-threatening bleeding if immediate
haemostatic support is required. Based on studies with PCCs
in preclinical models and in healthy volunteers, administra-
tion could start at a dose of 25 U/kg and can be repeated if
clinically indicated. Future studies might provide more infor-
mation on dosing, and whether dosing should be adapted to
the NOAC used. Activated prothrombin complex concentrates
(Feibas, 50 IE/kg, with a maximum of 200 IE/kg/day), could be
considered if it is readily available in the hospital.
The place of recombinant activated factor VIIa (NovoSevens,
90 mg/kg) needs further evaluation. The use of other pro-
coagulants such as antiﬁbrinolytics (e.g. tranexamic acid or
aminocaproic acid) or desmopressin (especially in special situa-
tions with associated coagulopathy or thrombopathy) can be
considered, though there are almost no clinical data of their
effectiveness in NOAC-associated bleeding, and their use does
not substitute the above mentioned measures. Fresh frozen
plasma will not be of help to reverse anticoagulation, but may
be indicated to expand plasma volume in patients who require
massive transfusion. In the absence of a vitamin K deﬁciency or
a treatment with VKAs, vitamin K administration has no role in
the management of a bleeding under NOACs. Similarly, prota-
mine reverses the anticoagulant effects of heparin, but has no
role in case of NOAC-associated bleeding.Table 9 – Last intake of drug before elective surgical interventi11. Patients undergoing a planned surgical
intervention or ablation
About one-quarter of patients that are in need for anti-
coagulant therapy require temporary cessation within 2 years.
Both patient characteristics (kidney function, age, history of
bleeding complications, concomitant medication) and surgical
factors should be taken into account while deciding when to
discontinue and restart the drug (Table 9). We recommend the
development of an institutional guideline and a hospital-wide
policy concerning post-operative anticoagulation manage-
ment in different surgical settings.
For interventions with no clinically important bleeding
risk (Table 10), it may be more practical to have the inter-
vention scheduled 18–24 h after the last intake, and then
restart 6 h later. For procedures with a minor bleeding risk, it
is recommended to discontinue NOACs 24 h before the
elective procedure and for procedures that carry a risk for
major bleeding to take the last NOAC 48 h before (Table 9).
For dabigatran, a more graded pre-intervention termination
depending on kidney ﬁction has been proposed, both for low-
and high-risk interventions.
Some coagulation tests (aPTT and PT) may provide a
semiquantitative assessment of dabigatran and FXa inhibi-
tors, respectively, but a strategy that includes normalisation
of the aPTT or PT prior to elective/urgent interventions has
not been validated.
For procedures with immediate and complete haemosta-
sis, the NOAC can be resumed 6–8 h after the intervention.
For many surgical interventions, however, resuming full dose
anticoagulation within the ﬁrst 48–72 h after the procedure
may carry a bleeding risk that could outweigh the risk of
cardio-embolism. One also has to take into account the
absence of a speciﬁc antidote.
For procedures associated with immobilisation, it is con-
sidered appropriate to initiate a reduced venous thrombo-
prophylactic or intermediate dose of low molecular weight
heparins (LMWH) 6–8 h after surgery, whereas therapeutic
anticoagulation by restarting NOACs is deferred 48–72 h afteron.
Table 11 – Recommendations concerning new onset AF in
patients with a recent (o1 year) ACS.
1. In patients with low or moderate atherothrombotic risk (GRACE
risko1 1 8), VKAs in monotherapy could be considered after 1–3
months (or 6 months in case of DES), especially when the
bleeding risk is elevated (HAS-BLED Z3)
2. In patients with high atherothrombotic risk (GRACE risk 4118),
additional single antiplatelet therapy (preferably clopidogrel)
might be necessary, especially when their bleeding risk is
acceptable (HAS-BLED o3)
3. Dual antiplatelet therapy without additional anticoagulation
might be an alternative for patients with a low CHA2DS2-VASc
score (i.e. r1) but high residual atherothrombotic risk (i.e.
GRACE risk score 4118)
4. If a NOAC would be indicated, a FXa inhibitor might be preferred
in view of the small but insigniﬁcant increase in the risk of
Table 10 – Classiﬁcation of elective surgical interventions
according to bleeding risk.
Interventions not necessarily requiring discontinuation of
anticoagulation
Dental interventions
Extraction of 1–3 teeth
Paradontal surgery
Incision of abscess
Implant positioning
Ophthalmology
Cataract or glaucoma intervention
Endoscopy without surgery
Superﬁcial surgery (e.g. abscess incision; small dermatologic
excisions;… )
Interventions with low bleeding risk
Endoscopy with biopsy
Prostate or bladder biopsy
Electrophysiological study or radiofrequency catheter ablation
for supraventricular tachycardia (including left-sided ablation via
single transseptal puncture)
Angiography
Pacemaker or ICD implantation (unless complex anatomical
setting, e.g. congenital heart disease)
Interventions with high bleeding risk
Complex left-sided ablation (pulmonary vein isolation; VT
ablation)
Spinal or epidural anaesthesia; lumbar diagnostic puncture
Thoracic surgery
Abdominal surgery
Major orthopaedic surgery
Liver biopsy
Transurethral prostate resection
Kidney biopsy
For each patient, individual factors relating to bleeding and
thrombo-embolic risk need to be taken into account, and be
discussed with the intervening physician.
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and efﬁcacy of the use of a reduced dose of the NOACs,
such as those used for the prevention of VTE after hip/knee
replacement.
For AF patients undergoing pulmonary vein isolation,
there is some emerging information available on the use of
dabigatran. There is no published data on the peri-
interventional use of FXa inhibitors undergoing catheter
ablation. Too aggressively shortened peri-procedural cessa-
tion of NOACs and/or no bridging may be less safe when
compared with continued VKA administration and ablation
under an INR between 2.0 and 3.0.myocardial infarction with dabigatran, but this needs to be
weighed against the overall perceived clinical effect (which was
not impacted for dabigatran)
5. If dabigatran would be indicated, a lower dose (110 mg bid)
might be preferred, in combination with low-dose aspirin or
with clopidogrel
6. Ultra-low-dose rivaroxaban (2.5 mg BID or 5 mg BID) in
combination with DAPT has not been evaluated in the setting of
AF and can currently not be recommended
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy.12. Patients undergoing an urgent surgical
intervention
If an emergency intervention is required, the NOAC should be
discontinued. Surgery or intervention should be deferred, if
possible, until at least 12 h and ideally 24 h after the last dose.
Evaluation of common coagulation tests (aPTT for DTI;
sensitive PT for FXa inhibitors) or of speciﬁc coagulation test
(dTT for DTI; chromogenic assays for FXa inhibitors) can beconsidered if there is concern about the pharmacokinetic
waning of the anticoagulant effect (e.g. renal insufﬁciency
and/or concomitant conditions).
Nevertheless, such strategy has never been evaluated, and
therefore cannot be recommended and should not be used
routinely.13. Patient with atrial ﬁbrillation and coronary
artery disease
The combination of AF and coronary heart disease is a
common clinical setting. Unfortunately, there is not sufﬁ-
cient data available to optimally guide clinical practice in
such settings. Moreover, new antiplatelet agents have
entered the market for acute coronary syndromes (ACS),
adding to uncertainty on how to use those in combination
with VKAs or NOACs when both ACS and AF converge in a
given patient. For the sake of clarity, we have opted to deﬁne
three clinical scenarios with many different subscenarios,
and proposed practical instructions for each: (i) ACS manage-
ment in an AF patient on NOAC; (ii) management of the
patient with a recent ACS (1 year) who develops new-onset
AF (Table 11); and (iii) development of AF in a patient with a
history of coronary heart disease, but without ACS within the
last year (Table 12). Given the complexity of these recom-
mendations, we refer to the full document. The type and
level of anticoagulation as well as single vs. dual antiplatelet
therapy in combination with NOAC, and its duration, need to
Table 12 – Recommendations concerning new onset AF in
patients with a remote (41 year) ACS.
1. As VKAs alone are superior to aspirin post-ACS, anticoagulation
without additional antiplatelet agents is considered sufﬁcient
for most AF patients with stable CAD
2. As the advantages of NOACs over VKAs are likely to be
preserved in stable CAD patients with AF, NOACs may be safe
and effective alternatives to VKAs
3. In general, no preference is given to either one of the NOACs
although a small increase was noted with dabigatran (but
without impacting overall clinical beneﬁt)
4. If dabigatran is chosen, a lower dose (110 mg bid) plus low-dose
aspirin might be a sensible option (or clopidogrel in case of
allergy to aspirin) especially in patients with high
atherothrombotic risk and low bleeding risk
ACS, acute coronary syndrome; bid, twice daily; CAD, coronary
artery disease.
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which are highly needed, may change the management
options.14. Cardioversion in a new oral
anticoagulant-treated patient
No prospective data are available concerning the safety of
cardioversion under NOAC treatment. Observational data
from the RE-LY, ROCKET-AF, and ARISTOTLE trials did not
show any difference in the number of strokes or systemic
embolisms, and that the stroke rate was comparable with
that in prior trials with other forms of anticoagulation, with
or without TEE guidance. Since there is no coagulation assay
available for NOACs that provides information on effective
anticoagulation over the past 3 weeks and because patient
compliance may be variable, it is mandatory to explicitly ask
the patient about adherence over the last weeks and to
document the answer in the ﬁle. If compliance with NOAC
intake can be reliably conﬁrmed, cardioversion seems accep-
tably safe. However, a prior TEE should be considered if there
is doubt about compliance.15. Patients presenting with acute intracranial
bleeding or ischaemic stroke while on new oral
anticoagulants
15.1. The acute phase
Guidelines for the treatment of intracerebral haemorrhage
under oral anticoagulants are limited to strategies for the
reversal of VKAs. By analogy to patients being treated
with warfarin, the coagulation status of patients under NOAC
who have acute or (apparently) on-going life-threatening
bleeding such as intracranial haemorrhage should be cor-
rected as rapidly as possible. Measures in this regard werediscussed in ‘Management of bleeding complications’. For
ischaemic stroke, thrombolytic therapy with recombinant
tissue plasminogen activator is not recommended in patients
under therapy with anticoagulants. As plasma half-life of
NOACs range between 8 and 17 h, thrombolytic therapy
cannot be given within 48 h after the last administration of
NOAC. This is an arbitrary recommendation, which is yet to
be tested. We believe that only in exceptional single cases in
which reliable coagulation assessment (with speciﬁc tests) is
within the normal reference range, the use of ﬁbrinolytic
agents can be considered. If NOACs have been administered
within the last 48 h and/or appropriate coagulation tests are
not available or abnormal, mechanical recanalization of
occluded vessels maybe considered as an alternative treat-
ment option.
15.2. Management of the post-acute phase
A history of a spontaneous intracerebral bleed constitutes a
contraindication against anticoagulation, unless the cause of
the intracerebral bleed has been reversed. By analogy to the
use of VKAs, the administration of NOACs may be restarted
10–14 days after intracerebral haemorrhage if cardioembolic
risk is high and the risk of new intracerebral haemorrhage is
estimated to be low. However, the same factors that are
predictive for embolic stroke are also predictive for haemor-
rhages. Non-pharmacological prevention strategies such as
ablation or occlusion of the atrial appendage should be
considered as potential substitutes.
Continuation of NOACs after ischaemic stroke depends on
the infarct size. Re-institution of anticoagulation in patients
with a transient ischaemic attack (TIA) can be considered
after 1 day, with small, non-disabling infarct after 3 days,
with a moderate stroke after 6 days, while large infarcts
involving large parts of the arterial territory will be treated
not before 2 (or even 3) weeks. If patient compliance and
therapeutic effect of coagulation have been assured (i.e. the
stroke must have occurred under adequate anticoagulation),
alternative causes for ischaemic stroke should be investi-
gated. After a TIA of cardioembolic origin, anticoagulation
treatment with NOACs can be started as soon as possible.
Bridging with LMWH is not required. Aspirin is not an
alternative option.16. New oral anticoagulants vs. vitamin K
antagonists in atrial ﬁbrillation patients with a
malignancy
Patients with malignancies are at an increased risk for throm-
boembolic events. Moreover, cancer therapy may induce
bleeding through local wounds (surgery), tissue damage
(irradiation), or systemic antiproliferative effects which will
reduce platelet count and function (chemotherapy and some
forms of irradiation). Antithrombotic therapy in patients with
AF and suffering a malignancy needs discussion between
cardiologist and oncologist. When anticoagulant therapy
needs to be initiated in a patient with malignancy, therapy
with VKAs or heparins should be considered over NOACs,
because of the clinical experience with these substances
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stably treated with a NOAC, who develop malignancies for
which they need to receive moderately myelosuppressive
therapies, continuation of NOACs may be defendable. When
a potent myelosuppressive chemotherapy or radiation ther-
apy is planned, temporary dose reduction or cessation of
NOAC therapy should be considered, and/ or speciﬁc mon-
itoring instituted, including repetitive full-blood counts
and regular monitoring of liver and renal function. Gastric
protection with PPI or H2-blockers is not contraindicated
and should even be considered in all patients treated with
anticoagulants.r e f e r e n c e n
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